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Objectives: To find out the average cost of hospitalization and length of hospital 
stay for patients infected with carbapenem-resistant bacteria and compare it with 
that of patients infected with carbapenem-sensitive bacteria. MethOds: A cross 
sectional study was carried out for 3 months and the data for hospitalization cost 
was collected for the patients with carbapenem resistant and carbapenem sensi-
tive infections from the medicine ICU and the microbiology department for 114 
patients with bacterial infections who were admitted to Intensive care unit. The 
data was analyzed for the type of infection and the average hospitalization cost. The 
median hospitalization cost was calculated for both the group of patients. Results: 
Out of 247 patients admitted in the ICU during a three month period 70 (28.34%) 
were found to be having carbapenem-resistant infections and 44 (17.81%) were 
found to have carbapenem-sensitive infections. The median length of stay in the 
hospital was 9 days for carbapenem-sensitive patients while 23.5 days in case of 
carbapenem-resistant patients. The median hospitalization cost was found to be 
40185 INR in case of carbapenem sensitive patients while it was 126889.5 INR in 
case of carbapenem-resistant patients. cOnclusiOns: Carbapenem-resistance is 
observed to be increasing the morbidity and cost burden on the patients substan-
tially. Increased length of hospital stay leads to an increase in the incidence of 
Nosocomial infections which further leads to the increased morbidity, mortality 
and cost burden on the society.
PIN33
TreaTmeNT of mrsa PNeumoNIa: ecoNomIcal aNd clINIcal 
comParIsoN of lINezolId Versus VaNcomycIN
Wilke M.1, Petrik C.2, Weber B.3, Kloss S.3
1Dr. Wilke GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Berlin, Germany, 3Pfizer Deutschland 
GmbH, Berlin, Germany
Objectives: Infections with methicillin resistant Staphylococcus aureus (MRSA) 
pathogens represent a substantial economic burden for the health care system. 
Although the expenses directly related to the antibiotics used for the treatment of 
MRSA infections are generally negligible in relation to the total MRSA-related hospi-
tal costs, the prices of the drugs often influence the therapy decisions. The objective 
of this study was to investigate – in a clinical routine setting – the overall costs of 
stay on intensive care unit (ICU) and the clinical effectiveness of treatment with lin-
ezolid compared to vancomycin in patients with MRSA pneumonia. MethOds: This 
was a retrospective analysis of reimbursement and medical data of adult patients 
who were treated for MRSA pneumonia in German hospitals between 2008 and 
2012. Propensity score adjustment was applied to reduce the effect of confound-
ing. Results: 95 of the 226 patients included received linezolid as initial therapy 
for MRSA pneumonia and 131 received vancomycin. The analysis of the total costs of 
stay on ICU did not reveal any major differences between the two treatment groups 
(cost ratio linezolid/vancomycin: 1.29; 95% confidence interval (CI): 0.84 – 1.98; p = 
0.24). Analyses of clinical data showed a decreased likelihood of therapy failure (= 
switch to another antibiotic) (logistic regression analysis; odds ratio linezolid/vanco-
mycin: 0.183; 95% CI: 0.052 – 0.647; p < 0.01) and a decreased risk of dying in hospital 
(Cox proportional hazard regression analysis; hazard ratio linezolid/vancomycin: 
0.508; 95% CI: 0.305 – 0.846; p < 0.01) in the linezolid group. cOnclusiOns: Despite 
higher drug acquisition costs, the total costs of stay on ICU were not significantly 
higher in patients receiving linezolid than in patients receiving vancomycin. The 
clinical effectiveness, on the other hand, was superior: Both, the rate of therapy 
failures and the all-cause hospital mortality rate were substantially lower in patients 
who received linezolid.
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Objectives: To compare treatment costs for the fixed dose combination (FDC) teno-
fovir and emtricitabine (TDF/FTC) versus FDC abacavir and lamivudine (ABC/3TC) 
each in combination with efavirenz (EFV) in treatment-naïve adults with HIV-1 
infection in Russia. MethOds: A mathematical model was developed in Microsoft 
Excel to evaluate costs of treatment, including drug (1st and 2nd lines of therapy) 
and patient management costs. In the model individuals remained on their current 
regimen or moved to the 2nd line of therapy after the first 48 weeks on therapy. 
Transition probabilities were based on the proportion of patients with viral response 
measured as HIV-1 RNA < 50 copies per milliliter from the clinical trial with TDF/FTC 
+ EFV vs ABC/3TC + EFV head-to-head comparison. Cost calculations were based on 
registered drug prices, reimbursement rates in public medical insurance and data 
on government procurement in Russia in 2014. Results: It was expected that after 
the 48 weeks of treatment 71.0% of patients in TDF/FTC + EFV group and 59.4% of 
ABC/3TC +EFV remain on the initial regimen. The total average costs per patient 
for 96 weeks of therapy, including drug (1st and 2nd lines of therapy) and patient 
management costs, were lower for TDF/FTC + EFV (€ 6,528) than for ABC/3TC + EFV 
group (€ 7,123). cOnclusiOns: FDC TDF/FTC in 1st line therapy in treatment-naïve 
adults with HIV-1 infection in combination with EFV was predicted to be cost-saving 
compared with FDC ABC/3TC+EFV for 96 weeks of treatment in Russian Federation.
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Objectives: After each negotiation between a health care provider and a payer, 
financial risks exists that may jeopardize the payer’s budget. Risk-sharing agree-
ments (RSAs) in medical care can be used to reassure payers on budget trajectory. 
This has grown during the recent years resulting from increased budget restric-
groups in high risk. The aim of the study is to evaluate the economic consequences 
of the vaccination against HAV in population groups at high risk and to com-
pare the results with the vaccination of all 1-year old children in the popula-
tion. MethOds: Cost-benefit analysis was performed based on epidemiologic 
data for the number of incidents in the high risk groups and the treatment cost of 
the HAV infected individuals. Those costs were compared with the cost of vaccina-
tion. Two vaccination scenarios were created 1. Prophylactic one dose vaccination 
and 2. One initial and one buster dose application. The validity of the results was 
tested with sensitivity analysis using tornado diagram. Results: The vaccina-
tion of all people in the high risk group (n= 32 606) induces savings for the health 
care system because the cost of vaccination is less than the cost of treatment of 
the people with HAV infection (n= 4565). The cost of vaccination varies from € 1 
257 322 to € 2 514 646 depending on the vaccination regimen: “first scenario” and 
“second scenario”, respectively. The expenditures for infected peoples’ therapy 
are € 2 547 254. Thus the net savings account for € 1 289 932 and € 32 608, respec-
tively. cOnclusiOns: The analysis confirms that the vaccination against hepa-
titis A infection is cost-saving for the health care if performed in groups at high 
risk and in the periods of epidemic outbreaks.
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Objectives: The new wave of HCV drugs reaching the market in 2014 offer higher 
cure rates and shorter treatment times; however, the new antivirals have been met 
with concerns regarding the costs associated with the new drugs by payors and the 
WHO. We have set out to examine the costs of treatment with sofosbuvir, compared 
to first generation antivirals in eight countries. MethOds: We examined the ex-
manufacturer price of sofosbuvir, telaprevir and boceprevir in Norway, Denmark, 
Germany, Luxembourg, Portugal, Slovenia, Turkey, and the United States. Treatment 
costs were calculated using standard of care protocols for treatment of HCV genotype 
1, including individual daily dosage strength and length of recommended treatment 
for each antiviral. Interferon and ribavirin costs, any potential discounts or rebates 
negotiated with payors and potential follow-up courses of therapy for sofosbuvir were 
excluded from the study. Prices were extracted from IHS Life Sciences’ international 
pricing database POLI. All foreign currency was converted to USD using XE Currency 
Converter for comparison. Results: Costs of treatment with sofosbuvir varied signif-
icantly across the eight countries, being highest in the US at USD84,000 then Portugal 
at USD75,816 down to USD52,051 in Norway. Telaprevir and boceprevir treatment costs 
range from a low of USD21,534 and USD14,111 in Turkey respectively, to a high of 
USD66,155 and USD40,120 in the US. On average across the eight countries, treatment 
with sofosbuvir was 104% higher than telaprevir, and 187% higher than boceprevir, 
based on the list price. cOnclusiOns: Our preliminary assessment has highlighted 
the variable treatment costs of HCV antivirals across countries. Comparisons of treat-
ment costs with next generation treatments versus first-generation antivirals will 
see expenditure for HCV therapeutics increase significantly. However, sofosbuvir has 
demonstrated cure rates of over 95% in genotype 1 HCV patients with a favourable 
safety profile, thus reducing costs of re-treatment, medical visits, and treatment of 
advanced liver disease.
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Objectives: To prevent reactivation of hepatitis B virus (HBV) following chemother-
apy or immunosuppressive therapy, appropriate clinical managements including 
HBV screening and antiviral prophylaxis for patients at risk of reactivation should 
be provided. Cost information of managing HBV reactivation is needed to evaluate 
cost-effectiveness of HBV prevention strategies in Japan. MethOds: Annual number 
of patients who have received cancer chemotherapy, biologic therapy for rheumatoid 
arthritis, or stem-cell / organ transplantation was estimated using information of 
national statistics and expert opinions. Costs of HBV screening and antiviral prophy-
laxis were calculated by following the HBV reactivation management guideline and 
reimbursement prices. A Markov model was created to compare two vaccination 
strategies of HBV infections (current selective vaccine program vs. new universal 
vaccine program) by considering risk of receiving chemotherapy or immunosuppres-
sive therapy, management costs of HBV reactivation, and disease-specific mortality, 
during 90 years of follow-up. Results: Costs for HBV reactivation management were 
estimated 688 yen per person in selective vaccination strategy compared with 350 
yen per person in universal vaccination strategy, with annual discount rate of 3%. 
On one-way sensitivity analysis, estimated costs were sensitive to annual discount 
rates and risks of HBV infections. cOnclusiOns: Absolute difference in the HBV 
management costs was relatively small compared with vaccine program costs. Since 
the management of HBV reactivation was not always provided for all patients at risk, 
a further cost analysis should be conducted by reflecting real-world clinical practice.
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Objectives: To examine the impact on costs and outcomes that may occur in 
neutropenic patients when treating for suspected invasive fungal infections (IFIs) 
caused by Aspergillus with typical empirical approach (EA) versus the recently pro-
posed “diagnostic-driven” (DD) approach in China. MethOds: A decision-analytic 
model was used to estimate total costs and predicted survival associated with EA 
and DD approaches in Shanghai, China. The population included patients aged 
> = 18 years with hematological malignancies or autologous/allogeneic stem cell 
transplantation expected to be neutropenic for > = 10 days, and without prophylactic 
antifungal treatment. Rates of IFI incidence, IFI captured by EA, overall mortality, and 
IFI-related mortality (10.9%, 30%, 10.7% and 28.6%, respectively) were obtained from 
the literature. Survival rates for each strategy were generated based on the propor-
tion of patients with identified and appropriately treated IFI. Treatment patterns 
with EA and DD approaches and resource use assumptions were based on the opin-
ion of five clinicians from three top hospitals in Shanghai. The total medical costs (in 
2014 Chinese Yuan) included antifungal drug cost, treatment-related adverse events 
cost, and cost of other medical resources. City-specific costing sources were used 
wherever possible. Results: Both approaches had similar survival rates (90.76% 
vs. 91.33% for EA and DD, respectively). Antifungal drug cost per patient was ¥2,813 
for EA and ¥2,307 for DD strategy. Although DD patients incurred a higher cost on 
PCR/GM testing (¥111 vs ¥88), the total medical costs of DD were substantially lower 
(¥2,563) than that of EA strategy (¥4,298) due to fewer patients receiving antifungal 
agents (DD: 7.4%; EA: 12.5%) with targeted IFI treatment. cOnclusiOns: This study 
suggests that the DD approach has the potential to initiate antifungal treatment in 
a more targeted population. It is expected to be a cost saving management strat-
egy for immunocompromised patients with suspected IFI in the context of China.
PIN39
The burdeN of closTrIdIum dIffIcIle (cdI) INfecTIoN IN hosPITals, IN 
deNmark, fINlaNd, Norway aNd swedeN
Nordling S.1, Anttila V.J.2, Norén T.3, Cockburn E.1
1Astellas Pharma a/s, Kastrup, Denmark, 2Helsinki University Central Hospital, Helsinki, Finland, 
3Department of Infectious Diseases, Örebro, Sweden
Objectives: Calculate the hospital cost of treating patients with Clostridium dif-
ficile (CDI) in Denmark, Finland, Norway and Sweden. MethOds: National patient 
databases from each country provided the number of patients, hospitalisations 
and length of stay (LOS) for CDI patients (ICD-10 code A047); year 2011 in Finland 
and Sweden and year 2012 in Denmark and Norway. In Norway and Sweden 
hospitalisation cost was based on the DRG cost for CDI patient and in Denmark 
and Finland the cost per bed day. Results: Sweden had the highest number 
of CDI patients and hospitalisations due to CDI during one year (3,425 patients 
and 4,723 hospital stays), then Finland (1,929 patients and 2,587 hospital stays), 
Denmark (1,804 patients and 2,465 hospital stays) and Norway (1,126 patients and 
1,418 hospital stays). On average the patients in Sweden were hospitalised with 
CDI diagnosis 1.38 times during one year and the corresponding figures was in 
Denmark 1.37, Finland 1.34 and Norway 1.26. The mean LOS for patients with CDI 
as primary diagnosis varied from 7.0 days in Norway to 14.7 days in Finland (9.0 
days, Denmark and 8.6 days, Sweden). The mean cost per CDI hospitalisation was 
lowest in Norway (€ 4,073 per patient), followed by Sweden (€ 6,261 per patient), 
Denmark (€ 7,234 per patient), and Finland (€ 10,231 per patient). The total cost for 
treating the hospitalised CDI patients during one year was approximately € 11 
million in Norway (5.1 million people), € 15 million in Finland (5.4 million people), 
€ 18 million in Denmark (5.6 million people) and € 30 million in Sweden (9.7 million 
people). cOnclusiOns: The total cost of treating the CDI patients ranges between 
€ 11-30 million per country and year, and approximately 26-38% of these costs are 
due to recurrence of CDI. By lowering the number of recurrences, there would be 
a potential for large cost savings.
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Objectives: Detailed and valid information on burden of disease is an indispen-
sable cornerstone for cost-effectiveness analyses. The aim of this study was to 
estimate the epidemiological and economic burden of varicella and herpes zoster 
(HZ) in Germany in order to generate important data for a subsequent model-
based analysis. MethOds: Analysis of the epidemiology and the one-year costs 
of varicella-zoster virus-related diseases/complications were based on 2010/2011 
claims data from a large German sickness fund. Insurants were included in the 
study when they had a varicella and/or HZ diagnosis in 2010, and then were fol-
lowed for one year after the date of the initial diagnosis. Disease-attributable 
costs were either calculated by diagnosis-specific identification of cost items or by 
use of a control group approach. Results: The study population included 12,710 
insurants with varicella and 35,636 insured persons with HZ. Age-standardised 
incidence rates were 1.55 and 5.5 per 1,000 person-years for varicella and HZ, 
respectively. The most frequent complication of HZ was post-herpetic neuralgia 
(PHN) with an overall proportion of 20.76%, ranging from 2.66% under the age of 10 
years to 26.03% in the age group of 80 years and above. When using a time-based 
algorithm instead of a pure diagnosis code-based approach overall PHN proportion 
was much lower (5.29%). Average direct costs of varicella were € 76.41, ranging from 
€ 45.92 in children < 5 years of age to € 444.28 in people aged ≥ 60 years. Direct costs 
of HZ (including PHN) were € 238.47 with a range from € 88.51 in children < 10 years 
of age to € 504.40 in people aged ≥ 80 years. cOnclusiOns: Varicella-zoster virus-
related diseases/complications cause a remarkable epidemiological and economic 
burden on the German health care system. Incidence and costs of varicella and 
HZ are highly age-dependent. Furthermore, the proportion of PHN was strongly 
influenced by the algorithm used to identify PHN cases.
tions. Typically, RSAs have been used for costly products for diseases with a high 
unmet need such as in oncology. To date, experience with RSAs in vaccines is 
limited. In this conceptual research we intend to identify RSAs that would be 
relevant and operable for vaccination programs. MethOds: We described the 
different types of uncertainties and associated financial risks a vaccine payer 
faces in the real-world setting. We conducted a literature review to list the vari-
ous RSAs proposed in the field of therapeutics. We then assessed how existing 
RSAs can mitigate those vaccines payers’ risks and evaluated those contracts for 
a hypothetical vaccine. Results: Vaccine specificities (few doses, potentially a 
large target population, herd effect and delayed benefit) need to be accounted 
for when designing RSAs. Financial risks in vaccination budget may arise from 
uncertainty on effectiveness/safety, uptake, supply, and real-world implementa-
tion. RSAs, categorized in either cost-sharing or performance-based risk-sharing, 
could enable vaccine payers to diminish those risks. As for drugs, cost-based 
deals would be easier to implement for vaccines than performance-based RSAs. 
The second should only be used when vaccine effects are observed on the 
short-term. Insurance mechanisms such as real-option pricing can be used to 
quantify the risk and price the associated RSA. cOnclusiOns: RSA can be used 
to mitigate financial risk associated with the access to vaccines. Based on the 
risks they entail, RSAs for vaccines can be viewed as real-option offered by the 
manufacturer to the payer. However their practical implementation is likely to 
differ from therapeutics.
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Objectives: As evidenced in ADVANCE and IDEAL studies, sustained virologic 
response (SVR) rate in treatment-naïve (TN) CHC patients increased from the level 
of 40% to about 75% when TVR was added to standard of care. In this cost-effective-
ness model, PR is compared with TVR triple therapy (with response guided treat-
ment approach) in TN CHC patients. MethOds: Analysis population includes TN 
patients infected with genotype 1 HCV. Progression of HC is simulated by a Markov 
model with 1-year duration of cycles within life-time horizon. The sources of clinical 
inputs are ADVANCE and IDEAL studies, in which TN CHC patients had been ran-
domized to TVR+P2aR or P2aR and to TVR+P2bR or P2bR, respectively. The sources 
of economic inputs are the drug price list (National Ministry of Health, June 2014) 
and procedure price list (National Institution of Security, April 2014). The analysis 
was performed from the point of view of the governmental payer, with direct costs 
only. The discount rate was set at 2%, national GDP per capita: 8.009€ , year 2013, 
currency rate: 2.80 TL/Euro. Results: Total costs of strategies were 21.938€ , 17.933€ 
and 17.932€ , for TVR, P2aR and P2bR, respectively. Corresponding QALYs were 16.19, 
15.64 and 15.57 years. Therefore 0.55 and 0.62 QALYs were gained with extra costs of 
4.018€ and 4.109€ (vs P2aR and P2bR, respectively). Thus, TVR was cost-effective as 
compared to P2aR and P2bR, taking the national GDP as the informal willingness-
to-pay threshold. cOnclusiOns: Although the initial cost of treatment with TVR 
is higher than peg-interferon and ribavirin, in CHC patients, the cost savings that 
will be realized with the very successful clinical prognosis make treatment with 
TVR clearly cost-effective. Therefore, all TN CHC patients should be considered as 
a candidate of TVR treatment.
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Objectives: As evidenced in REALIZE study, sustained virologic response (SVR) rate 
increased from the 17% to 63% in treatment-experienced (TE) chronic hepatitis C 
(CHC) patients, when telaprevir (TVR) was added to standard of care. In this cost-
effectiveness model, PR is compared with TVR triple therapy (with response guided 
treatment approach) in TE CHC patients. MethOds: In this cost-effectiveness model, 
TVR+PR is compared with PR. Analysis population includes TE and unresponsive or 
failed patients infected with genotype 1 HCV. Progression of CHC is simulated by a 
Markov model with 1-year duration of cycles within life-time horizon. The source 
of clinical inputs is REALIZE study, in which TE CHC patients had been randomized 
to TVR+PR or PR. The sources of economic inputs are the drug price list (National 
Ministry of Health, June 2014) and procedure price list (National Institution of Security, 
April 2014). The analysis was performed from the point of view of the governmental 
payer, with direct costs only. The discount rate was set at 2%, national GDP per capita: 
8.009€ , year 2013, currency rate: 2.80 TL/Euro. Results: Total costs of strategies (medi-
cations and other components) were 29.735€ , 28.938€ and 28.343€ , for TVR, P2aR and 
P2bR, respectively. QALYs gained was 1.25 years with TVR+PR with extra costs of 797€ 
and 1.393€ (vs P2aR and P2bR, respectively). Corresponding ICER values were 640€ /
QALY and 1.118€ /QALY for TVR+PR vs P2aR and TVR+PR vs P2bR, respectively. Thus, 
TVR was definitely cost-effective. cOnclusiOns: Although the initial cost of treat-
ment with TVR is higher than PR, in CHC patients, the cost savings that will be realized 
with the very successful clinical prognosis make treatment with TVR clearly very cost-
effective and close to cost neutral. Therefore, all TE CHC patients who not responded 
or failed after a response, should be considered as a candidate of TVR treatment.
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